Qiagen N.V. (QGEN)

Market Cap	8.85B
Revenue (ttm)	1.97B
Net Income (ttm)	341.30M
Shares Out	221.36M
EPS (ttm)	1.50
PE Ratio	25.80
Forward PE	18.83
Dividend	$1.32 (3.30%)
Ex-Dividend Date	Jan 30, 2024

Volume	886,370
Open	39.64
Previous Close	39.47
Day's Range	39.63 - 40.14
52-Week Range	34.74 - 47.70
Beta	0.42
Analysts	Buy
Price Target	50.51 (+26.28%)
Earnings Date	Apr 29, 2024

About QGEN

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample mate...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN

Financial Performance

In 2023, Qiagen's revenue was $1.97 billion, a decrease of -8.23% compared to the previous year's $2.14 billion. Earnings were $341.30 million, a decrease of -19.35%.

Analyst Forecast

According to 8 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $50.51, which is an increase of 26.28% from the latest price.

Price Target

$50.51

(26.28% upside)

Analyst Consensus: Buy